Zhang, M. et al. Nat Commun 12, 1751 (2021).
Publication Category: Selected
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Scagliotti, G. V. et al. Lancet Respir Med 7, 569-580 (2019).
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Maio, M. et al. Lancet Oncol 18, 1261-1273 (2017).
Novel insights into mesothelioma biology and implications for therapy
Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Nat Rev Cancer 17, 475-488 (2017)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Krug, L. M. et al. Lancet Oncol 16, 447-456 (2015).